Hanna Iderberg

TL;DR: It is concluded that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease.

TL;DR: This article will review models developed in non-human primate and rodents to reproduce motor complications induced by dopamine replacement therapy and the recent breakthroughs represented by mouse models and the relevance of rodents in relation to non- human primate models are discussed.

TL;DR: Targeting 5-HT1A receptors with selective biased agonists exerts distinct effects in the rat model of PD and LID and could potentially translate to superior antidyskinetic and L-DOPA dose-sparing effects in PD patients.

TL;DR: NLX-112 could exhibit a novel therapeutic profile, combining robust anti-dyskinetic properties without impairing the therapeutic properties of L-DOPA, and with additional beneficial effects on non-motor (affective) symptoms.

TL;DR: Results indicate that a pharmacological stimulation of mGlu4 lacks intrinsic antidyskinetic activity, but may have DOPA-sparing activity in Parkinson's disease, and for the latter indication, mGLU4 PAMs appear to provide a better option than orthosteric agonists.